Nucleic Acid Therapeutics CDMO Market Size & Growth Forecast 2026–2035, By Segments (Type, End-use, Service, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Nucleic Acid Therapeutics CDMO Market size was valued at USD 17.12 Billion in 2025 and is anticipated to grow at a 14.1% CAGR from 2026 to 2035, surpassing USD 64.03 Billion by 2035. The industry revenue for 2026 is assessed at USD 19.28 billion.

• Base Year Value (2025): USD 17.12 Billion
• CAGR (2026-2035): 14.1%
• Forecast Year Value (2035): USD 64.03 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Nucleic Acid Therapeutics CDMO Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America leads with 42.61% share due to strong CDMO base, advanced biopharma outsourcing, and mature regulatory systems supporting complex nucleic acid manufacturing and scale-up needs.
  • Asia Pacific is growing at 15.79% CAGR driven by rising outsourcing demand, expanding manufacturing capacity, and increasing adoption of cost-efficient and scalable CDMO services.

• Segment Momentum:

  • RNA-based Therapies held a 63.68% market share in 2025 because developers depend on CDMOs for specialized process development, analytical support, and scalable manufacturing across complex RNA production workflows.
  • Government and academic research institutes are growing fastest as they increasingly rely on CDMOs to transform early-stage nucleic acid discoveries into clinically usable materials without building commercial manufacturing infrastructure.

• Market Expansion Drivers:

  • Rapid expansion of RNA and gene therapy pipelines driving outsourced manufacturing demand.
  • Increasing prevalence of genetic disorders accelerating demand for personalized nucleic acid therapies.
  • Growing adoption of one-stop CDMO models improving end-to-end biologics development efficiency.

• Leading Market Participants:

  Top players in the nucleic acid therapeutics CDMO market include WuXi AppTec Co., Ltd. (China), Danaher Corporation (United States), Merck KGaA (Germany), Curia Global, Inc. (United States), Agilent Technologies, Inc. (United States), Ajinomoto Co., Inc. (Japan), LGC Limited (United Kingdom), BioSpring GmbH (Germany), Exothera S.A. (Belgium), KNC Laboratories Co., Ltd. (Japan).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 17.12 Billion
  • 2026 Market Size: USD 15.2 billion
  • Projected Market Size: USD 64.03 Billion by 2035
  • Growth Forecasts: 14.1% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: RNA-based Therapies (Type) | Biotech Companies (End-use) | Manufacturing Services (Service) | Infectious Diseases (Application)
  • Emerging Opportunity Segment: Gene Therapy (Type) | Government & Academic Research Institutes (End-use) | Process Development and Optimization (Service) | Infectious Diseases (Application)

Market Growth Drivers and Industry Trends

Rapid expansion of RNA and gene therapy pipelines driving outsourced manufacturing demand

As RNA modalities and gene therapy candidates move from discovery into preclinical and clinical stages, biopharma companies are turning to specialist partners that can handle complex oligonucleotide synthesis, plasmid production, analytical development, and GMP scale-up without the delay of building internal capacity. This is driving demand for the nucleic acid therapeutics CDMO market because pipeline growth translates directly into more process development programs, more clinical supply requirements, and a greater need for flexible manufacturing slots. Smaller developers in particular rely on outsourcing to compress development timelines and access platform know-how in formulation, purification, and regulatory documentation, which supports market expansion by shifting a larger share of technical execution to established CDMOs.

Increasing prevalence of genetic disorders accelerating demand for personalized nucleic acid therapies

A rising burden of genetic disorders is reshaping treatment development toward highly targeted nucleic acid approaches designed around specific mutations, patient subgroups, or rare disease pathways. That dynamic is influencing market adoption in the nucleic acid therapeutics CDMO market by increasing the volume of specialized projects that require customized process design, small-batch GMP manufacturing, and precise analytical control rather than standardized large-scale production. As therapy developers pursue patient-specific or narrowly defined indications, CDMOs become central to translating bespoke constructs into clinical-grade material, reinforcing market demand for partners with expertise in low-volume, high-complexity manufacturing workflows.

Growing adoption of one-stop CDMO models improving end-to-end biologics development efficiency

Biopharma sponsors are increasingly favoring integrated outsourcing models that combine development, manufacturing, testing, and regulatory support under one provider to reduce handoff risk and simplify program management. In the nucleic acid therapeutics CDMO market, this preference is strengthening market development by concentrating more of the value chain with CDMOs that can take a candidate from early process optimization through clinical and commercial production. The practical effect is shorter technology transfer cycles, tighter control over quality and timelines, and fewer coordination gaps between separate vendors, making one-stop providers more attractive for nucleic acid programs where process sensitivity and documentation continuity are critical.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rapid expansion of RNA and gene therapy pipelines driving outsourced manufacturing demand	2.00%	High	North America, Europe	High	Near Term
Increasing prevalence of genetic disorders accelerating demand for personalized nucleic acid therapies	1.80%	High	North America, Asia Pacific	High	Mid Term
Growing adoption of one-stop CDMO models improving end-to-end biologics development efficiency	1.50%	Moderate	Europe, North America	Emerging	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held a 42.61% share of the nucleic acid therapeutics CDMO market in 2025, bolstered by its established base of specialized contract development and manufacturing providers, strong biopharma outsourcing activity, and mature regulatory and quality systems. The region’s leadership is reinforced by its concentration of developers advancing oligonucleotide, mRNA, and related pipelines that require technically demanding process development, analytical testing, and GMP manufacturing. In practice, this creates steady demand for CDMO partners that can handle complex scale-up, technology transfer, and compliance requirements across clinical and commercial stages.

Asia Pacific is projected to expand at a 15.79% CAGR over the forecast period in the nucleic acid therapeutics CDMO market, driven by rising outsourcing to regional manufacturing platforms and expanding biopharmaceutical production capabilities. Growth is accelerating as developers look for capacity, cost efficiency, and faster execution for process development and manufacturing programs, while regional CDMOs continue building technical expertise in nucleic acid modalities. This is translating into greater adoption of Asia Pacific providers for both early-stage development work and larger-scale supply programs.

Regional Market Attractiveness & Strategic Fit Matrix
Parameter	North America	Asia Pacific	Europe	Latin America	MEA
Innovation Hub	Advanced	Developing	Advanced	Developing	Nascent
Cost-Sensitive Region	Low	Medium	Low	High	High
Regulatory Environment	Restrictive	Neutral	Restrictive	Neutral	Neutral
Demand Drivers	Strong	Moderate	Strong	Moderate	Weak
Development Stage	Developed	Developing	Developed	Developing	Emerging
Adoption Rate	High	Medium	High	Medium	Low
New Entrants / Startups	Moderate	Moderate	Moderate	Sparse	Sparse
Macro Indicators	Strong	Stable	Stable	Stable	Weak

Key Country Insights

United States

End-to-End Manufacturing

The U.S. nucleic acid therapeutics CDMO market focuses on integrated development and manufacturing for mRNA, siRNA, antisense oligonucleotides, and gene-editing platforms. U.S. customers increasingly seek scalable production, analytical testing, and regulatory support from specialized CDMO partners.

Japan

High-Purity Production

Japan advances nucleic acid therapeutics manufacturing by emphasizing production consistency, impurity control, and process reliability. Japanese CDMOs support pharmaceutical innovators with specialized expertise in complex oligonucleotide manufacturing and quality assurance.

South Korea

Flexible Development Capacity

South Korea is expanding CDMO capabilities for nucleic acid therapeutics through investments in modular manufacturing facilities and advanced production technologies. South Korean providers increasingly attract biotechnology companies requiring responsive process development and scalable manufacturing services.

Germany

GMP Manufacturing Expertise

Germany prioritizes high-quality GMP manufacturing, analytical characterization, and process optimization for nucleic acid therapeutics. German CDMOs continue expanding specialized production capabilities to support clinical and commercial development of advanced genetic medicines.

France

Integrated Analytical Support

France combines specialized analytical testing with process development services for nucleic acid therapeutics manufacturing. French CDMOs focus on helping developers accelerate product development through robust quality systems and regulatory-ready manufacturing operations.

Italy

Process Development Focus

Italy supports nucleic acid therapeutics CDMO services through expertise in formulation development, process optimization, and pharmaceutical manufacturing. Italian providers continue strengthening technical capabilities that improve production efficiency for innovative genetic therapies.

Segment Leadership and Growth Trends

  Type Segment Analysis: RNA-based Therapies (Largest Segment) vs Gene Therapy (Fastest-Growing Segment)

RNA-based Therapies held a 63.68% share of the nucleic acid therapeutics CDMO market in 2025, making this the leading type segment. its position is maintained through the strong outsourcing fit of RNA programs, where developers rely on CDMOs for specialized process development, analytical support, and scalable manufacturing across complex oligonucleotide and RNA workflows. The segment’s established project pipeline and recurring need for controlled production environments help preserve its dominant share in the nucleic acid therapeutics CDMO market.

Gene Therapy is emerging as the fastest-growing type segment in the nucleic acid therapeutics CDMO market as development activity increasingly shifts toward advanced therapeutic platforms that require highly specialized external manufacturing capabilities. Growth is being aided by the practical difficulty of building in-house viral vector and related production infrastructure, pushing sponsors toward CDMO partners with technical expertise and compliant capacity. Compared with more established modalities, Gene Therapy is gaining momentum because its manufacturing demands create a stronger need for outsourced development and production support.

End-use Segment Analysis: Biotech Companies (Largest Segment) vs Government & Academic Research Institutes (Fastest-Growing Segment)

Biotech Companies accounted for the largest share of the nucleic acid therapeutics CDMO market in 2025. Their lead position reflects a business model that depends heavily on outsourced development and manufacturing, especially where internal production capacity is limited and speed to clinic is essential. In the nucleic acid therapeutics CDMO market, biotech firms typically maintain active therapeutic pipelines while relying on external partners for process scale-up, quality systems, and specialized manufacturing execution, which supports their continued share leadership.

Government & Academic Research Institutes represent the fastest-growing end-use segment in the nucleic acid therapeutics CDMO market as translational research activity increasingly moves toward structured development pathways that require external manufacturing support. Their growth is being driven by the need to convert early-stage nucleic acid discoveries into clinically usable materials without investing in full commercial-grade production infrastructure. Relative to more established end users, these institutions are gaining momentum as they engage CDMOs to bridge the gap between research output and regulated therapeutic development.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Type	Gene Therapy, RNA-based Therapies	RNA-based Therapies	Gene Therapy
End-use	Pharmaceutical Companies, Government & Academic Research Institutes, Biotech Companies	Biotech Companies	Government & Academic Research Institutes
Service	Process Development and Optimization, Manufacturing Services, Analytical and Quality Control Services, Others	Manufacturing Services	Process Development and Optimization
Application	Rare Diseases, Genetic Disorders, Infectious Diseases, Others	Infectious Diseases	Infectious Diseases

Competitive Landscape and Market Positioning

Major players in the nucleic acid therapeutics CDMO market:

1. WuXi AppTec Co. Ltd. (China)

2. Danaher Corporation (United States)

3. Merck KGaA (Germany)

4. Curia Global Inc. (United States)

5. Agilent Technologies Inc. (United States)

6. Ajinomoto Co. Inc. (Japan)

7. LGC Limited (United Kingdom)

8. BioSpring GmbH (Germany)

9. Exothera S.A. (Belgium)

10. KNC Laboratories Co. Ltd. (Japan)

The nucleic acid therapeutics CDMO market is advancing through rapid scaling of specialized manufacturing capabilities tailored for next-generation genetic therapies. Strong emphasis on process optimization and advanced biologics production is enabling improved efficiency and regulatory readiness. The nucleic acid therapeutics CDMO market is expanding as demand grows for complex molecular therapeutics and precision medicine solutions.

Industry Development/News

Company Name	Date	Key Development
Hongene Biotech	Sep-25	Hongene Biotech secured a non-exclusive licensing agreement with UMass Chan Medical School to supply exNA monomers and modified oligonucleotides. This deal expands Hongene’s RNA chemistry CDMO portfolio, allowing it to support the development of next-generation RNA therapeutics beyond liver-targeted applications, including tissue-specific delivery platforms that require enhanced chemical stability.
Cohance Lifesciences	Aug-25	Cohance Lifesciences invested USD 2.8 million in a new cGMP oligonucleotide building block facility in Hyderabad. The facility adds 700 kg of annual capacity for modified nucleosides and locked nucleic acids (LNAs), strengthening the company's global CRDMO platform and supporting the supply chain needs of developers working on next-generation RNA-based therapeutics.
Sumitomo Chemical	Apr-25	Sumitomo Chemical established a new US-based CRO and CDMO operation to specialize in large-scale, high-purity guide RNA (gRNA) production. This investment directly supports the rapidly growing genome editing and CRISPR-based therapy market, providing the technical scale and purity standards required for commercial-grade manufacturing of gene-editing components.
Agilent Technologies	Jul-24	Agilent completed its USD 925 million acquisition of BioVectra, substantially expanding its oligonucleotide and CRISPR CDMO capabilities. The acquisition adds significant manufacturing scale across siRNA, antisense, mRNA, and lipid nanoparticle modalities, positioning Agilent as a comprehensive partner for the full-cycle development and fill-finish production of complex nucleic acid and gene-based medicines.
AGS Biologics	Mar-24	AGS Biologics received FDA commercial manufacturing clearance for its Milan site to produce Orchard Therapeutics’ Lenmeldy, a gene therapy for metachromatic leukodystrophy. This milestone demonstrates the company’s capacity to handle the complex, end-to-end manufacturing requirements of commercial-stage gene therapy products, highlighting the growing role of CDMOs in the delivery of transformative autologous cell-based treatments.